Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

X4 Pharmaceuticals

NASDAQ XFOR
$0.93 -0.0004 -0.04%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 11 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

185.67M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
141.88M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.09
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
199.99M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
10.72 %

Upcoming events X4 Pharmaceuticals

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart X4 Pharmaceuticals

Stock analysis X4 Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1.44 28.84
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
3.63 4.35
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-1.23 10.00
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.38 0.65
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-12,443.34 7.67

Price change X4 Pharmaceuticals per year

4.25$ 10.70$
Min Max

Summary analysis X4 Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure X4 Pharmaceuticals

Revenue and net income X4 Pharmaceuticals

All parameters

Stock news X4 Pharmaceuticals

All news
12 April 2023 в 21:15

X4 Pharmaceuticals Shares Rise 31% on WHIM Syndrome Drug Trial Data Release

12 April 2023 в 21:15

X4 Pharmaceuticals Shares Rise 31% on WHIM Syndrome Drug Trial Data Release

28 September 2022 в 19:51

X4 Pharmaceuticals Shares Continue to Rise, Up 17%

28 September 2022 в 19:51

X4 Pharmaceuticals Shares Continue to Rise, Up 17%

27 September 2022 в 15:20

X4 Pharmaceuticals Sees Positive Data From Mavorixafor Trial

27 September 2022 в 15:20

X4 Pharmaceuticals Sees Positive Data From Mavorixafor Trial

22 July 2022 в 15:26

X4 Pharmaceuticals stock price target cut to $5 from $9 at Stifel Nicolaus

13 December 2021 в 21:00

X4 Pharmaceuticals Down 34% After Presentations; Stifel Maintains Buy Rating

13 December 2021 в 21:00

X4 Pharmaceuticals Down 34% After Presentations; Stifel Maintains Buy Rating

About company X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Address:
61 North Beacon Street, Boston, MA, United States, 02134
Company name: X4 Pharmaceuticals
Issuer ticker: XFOR
ISIN: US98420X1037
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2017-11-16
Sector: Healthcare
Industry: Biotechnology
Site: https://www.x4pharma.com

On which stock exchange are X4 Pharmaceuticals (XFOR) stocks traded?

X4 Pharmaceuticals (XFOR) stocks are traded on NASDAQ.

What is the ticker of X4 Pharmaceuticals stocks (XFOR)?

The stock ticker of X4 Pharmaceuticals’s stocks or in other words, the code is XFOR. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does X4 Pharmaceuticals (XFOR) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, X4 Pharmaceuticals (XFOR) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are X4 Pharmaceuticals (XFOR) stocks traded?

X4 Pharmaceuticals (XFOR) stocks are traded on the NASDAQ exchange in dollars.

What is the price of X4 Pharmaceuticals (XFOR) stocks today?

The current price of X4 Pharmaceuticals stocks on 20.05.2024 is 0.928 dollars. per share.

What is the dynamics of X4 Pharmaceuticals (XFOR) stocks from the beginning of the year?

X4 Pharmaceuticals (XFOR) quotes have increased by 5.19% from the beginning of the year up to 0.928 dollars. per 1 stocks.

How much did X4 Pharmaceuticals (XFOR) stocks increase in мае 2024?

This month X4 Pharmaceuticals (XFOR) quotes have increased by -16.02% to 0.928 dollars. per share.

How much are X4 Pharmaceuticals (XFOR) stocks worth?

Today, on October, 20.05.2024 X4 Pharmaceuticals’s (XFOR) stocks cost 0.928 dollars..

What is the market capitalization of X4 Pharmaceuticals (XFOR)?

Capitalization is the market value of X4 Pharmaceuticals (XFOR) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 20.05.2024, the market capitalization of X4 Pharmaceuticals (XFOR) is estimated at about 185672199 dollars.